a) He did mention in a interview when asked "Where
Post# of 148185
b) As a businessman, he knows Leronlimab will have huge (and high margin) sales, and that's the best way to fund his ideas and researches. It's a match made in heaven. If I can see it, he knows it for sure.
c) CYDY is cheap before approval. He would become a multi-billionaire.
IMO (c) was the reason BOD did not buy it, and in the future they should fight for what he made while working on CytoDyn's data. They didn't want to the same as they did with RP. But Bruce is an amazing asset and source of revenue, IMO.